Burning Rock Biotech reported $77.2 million in revenue for fiscal year 2025, narrowing net losses to $7.9 million as of year-end. The company’s operational momentum is underscored by strong liquidity with nearly $68.4 million cash reserves, supporting ongoing investment in proprietary oncology molecular diagnostics. Incorporation offshore combined with China-based operations creates tax and regulatory complexity but also competitive leverage. Looking forward, the company’s growth opportunities hinge on expanding cancer screening adoption in China, regulatory approvals, and technological differentiation within a highly contested biotechnology landscape.